Smithkline Beecham Corporation v. Abbott Laboratories
United States Court of Appeals for the Ninth CircuitJune 24, 201411-17357California2,992 words
Opinion
Opinion
FOR PUBLICATION
UNITED STATES COURT OF APPEALS
FOR THE NINTH CIRCUIT
SMITHKLINE BEECHAM No. 11-17357
CORPORATION, DBA
GlaxoSmithKline, D.C. No. Plaintiff-Appellee, 4:07-cv-05702-CW
v.
ABBOTT LABORATORIES,
Defendant-Appellant.
SMITHKLINE BEECHAM No. 11-17373
CORPORATION, DBA
GlaxoSmithKline, D.C. No. Plaintiff-Appellant, 4:07-cv-05702-CW
v.
ORDER
ABBOTT LABORATORIES,
Defendant-Appellee.
Filed June 24, 2014
Before: Mary M. Schroeder, Stephen Reinhardt, and Marsha S. Berzon, Circuit Judges.
Order; Dissent by Judge O’Scannlain SUMMARY*
Equal Protection
The panel filed an order rejecting a sua sponte en banc call.
In its opinion filed January 21, 2014, the panel reversed the district court’s judgment in an antitrust case concerning a licensing agreement and the pricing of HIV medications. The panel held that classifications based on sexual orientation are subject to heightened scrutiny, and that in jury selection, equal protection prohibits peremptory strikes based on sexual orientation.